Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) Inventory Average (2018 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Inventory Average for 8 consecutive years, with $46.3 million as the latest value for Q2 2025.

  • On a quarterly basis, Inventory Average rose 21.68% to $46.3 million in Q2 2025 year-over-year; TTM through Jun 2025 was $46.3 million, a 21.68% increase, with the full-year FY2025 number at $48.5 million, up 22.83% from a year prior.
  • Inventory Average was $46.3 million for Q2 2025 at Ultragenyx Pharmaceutical, up from $45.5 million in the prior quarter.
  • In the past five years, Inventory Average ranged from a high of $46.3 million in Q2 2025 to a low of $15.1 million in Q3 2021.
  • A 5-year average of $32.8 million and a median of $33.9 million in 2023 define the central range for Inventory Average.
  • Peak YoY movement for Inventory Average: skyrocketed 41.8% in 2022, then increased 21.68% in 2025.
  • Ultragenyx Pharmaceutical's Inventory Average stood at $15.1 million in 2021, then soared by 60.58% to $24.3 million in 2022, then surged by 35.29% to $32.9 million in 2023, then soared by 34.31% to $44.2 million in 2024, then rose by 4.75% to $46.3 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Inventory Average are $46.3 million (Q2 2025), $45.5 million (Q1 2025), and $44.2 million (Q4 2024).